Ischemix Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.6M

Ischemix General Information

Description

Developer of therapeutic compounds intended for the treatment of serious diseases and conditions. The company's primary focus of the company is the development of a novel, and patented cytoprotective compound that has demonstrated efficacy in preclinical models of traumatic brain injury (TBI), enabling patients to protect against the damage effects associated with ischemia in the brain and other organs.

Contact Information

Website
www.ischemix.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 13 Pullard Road
  • Grafton, MA 01519
  • United States
+1 (508)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 13 Pullard Road
  • Grafton, MA 01519
  • United States
+1 (508)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ischemix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 05-Jun-2014 $6.6M Completed Pre-Clinical Trials
1. Early Stage VC Completed Startup
To view Ischemix’s complete valuation and funding history, request access »

Ischemix Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Ischemix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20070042962-A1 Peptide dependent upregulation of telomerase expression Inactive 04-Feb-2002
US-20050130881-A1 For upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals Inactive 25-May-2001
CA-2447292-A1 Peptide compounds for counteracting reactive oxygen species and free radicals Inactive 17-May-2001
EP-1401862-A2 Peptide compounds for counteracting reactive oxygen species and free radicals Inactive 17-May-2001
EP-1401862-A4 Peptide compounds for counteracting reactive oxygen species and free radicals Inactive 17-May-2001 C07K7/06
To view Ischemix’s complete patent history, request access »

Ischemix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Ischemix FAQs

  • When was Ischemix founded?

    Ischemix was founded in 1999.

  • Where is Ischemix headquartered?

    Ischemix is headquartered in Grafton, MA.

  • What is the size of Ischemix?

    Ischemix has 7 total employees.

  • What industry is Ischemix in?

    Ischemix’s primary industry is Biotechnology.

  • Is Ischemix a private or public company?

    Ischemix is a Private company.

  • What is Ischemix’s current revenue?

    The current revenue for Ischemix is .

  • How much funding has Ischemix raised over time?

    Ischemix has raised $32.6M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »